Proxy Votes Now

Home › Funds › BlackRock › iShares Genomics Immunology and Healthcare ETF

iShares Genomics Immunology and Healthcare ETF (IDNA) proxy voting record 2025-2026

Fund family: BlackRock · Filed by iSHARES TRUST (CIK 1100663) · SEC series S000065599

Ticker: IDNA (C000212225)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 501 with, 5 against, 7 abstentions (not counted as with management); 1 items carried no recommendation. Shareholder proposals: 0 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with BlackRock as a whole

The same two figures as BlackRock’s manager page (1,606,521 ballot items across 392 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsBlackRockItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)88.0%44093.6%1,355,861
Backed environmental and social shareholder proposals at US companiesn/a15.5%6,306

Where this fund voted differently from most BlackRock funds

Each ballot item this fund voted is set against the votes of the other BlackRock funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most BlackRock funds on 2 items (0.5% of the 431 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost BlackRock fundsMgmtResult
BIONTECH SE2026-05-15Elections to the Supervisory Board: Prof. Dr. Iris Loew-FriedrichAgainstFOR — 6 of 8 BlackRock fundsAgainst—
BIONTECH SE2026-05-15Elections to the Supervisory Board: Prof. Dr. Rudolf StaudiglAgainstFOR — 6 of 8 BlackRock fundsAgainst—

Download all 2 differences (CSV)

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections2390
Corporate Governance692
Say-on-Pay630
Compensation481
Audit-related470
Capital Structure440
Extraordinary Transactions40
Shareholder Rights and Defenses31
Other Social Issues21

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
MODERNA, INC.May 6, 2026$42M50
MODERNA, INC.November 12, 2025$21M20
REVOLUTION MEDICINES, INC.June 18, 2026$12M40
TWIST BIOSCIENCE CORPORATIONFebruary 5, 2026$9M50
EXELIXIS, INC.May 26, 2026$8M140
MERCK & CO., INC.May 26, 2026$8M183
REGENERON PHARMACEUTICALS, INC.June 12, 2026$7M70
VERTEX PHARMACEUTICALS INCORPORATEDMay 13, 2026$6M151

Notable votes against management

MeetingCompanyProposalFundMgmt
May 26, 2026MERCK & CO., INC.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026MERCK & CO., INC.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
May 13, 2026VERTEX PHARMACEUTICALS INCORPORATEDShareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalAgainstFor
June 25, 2026VALNEVA SEAuthorize Capital Issuances for Use in Employee Stock Purchase PlansForAgainst

Search this fund’s votes by company

519 ballot items at 52 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, iShares Genomics Immunology and Healthcare ETF (IDNA) voted at 52 shareholder meetings of 49 companies, on 519 ballot items in all. Where management made a recommendation, the fund followed it on 97.7% of the items and voted against it 5 times. Its most frequent area of disagreement was corporate governance (2 of its votes against management). It voted on 4 shareholder proposals. It voted FOR the board's own proposals less often than BlackRock's funds as a whole (88.0% against 93.6%). It voted differently from most BlackRock funds on 2 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of BlackRock’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.